HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new...
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks), under which the...
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development...
Driven by national industrial policy support and the comprehensive upgrading of public health needs, China’s biopharmaceutical industry has entered a new stage of high-quality...
Following a successful turnaround under the control of TR Capital, Vietnam's leading modern retail pharmacy chain has reached full profitability and is entering its...
Increasing interest in science-backed ingredients positions Singapore as a key gateway for European dairy innovation in Southeast Asia
The European Union is strengthening its engagement...
Everest Medicines announced that its substantial shareholder, CBC Group, purchased 600,500 ordinary shares of the Company on the market from 20 May 2026 to...
